Print this page
-
Understanding Sun Protection and Skin Examination Practices Among Hispanics.
Protocol: 132111Principal Investigator:
- Carolyn Heckman Ph.D. (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Evaluation of Circulating Tumor DNA (ctDNA) in Patients with Stage IIB and IIC Malignant Melanoma .
Protocol: 002122Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
Protocol: 092202Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
A Phase 3 Trial of Fianlimab (Anti-Lag-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma
Protocol: 092204Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies.
Protocol: 092205Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin
- 1
- 2